3.98
前日終値:
$4.05
開ける:
$4.03
24時間の取引高:
289.42K
Relative Volume:
1.86
時価総額:
$42.98M
収益:
-
当期純損益:
$-19.25M
株価収益率:
-2.236
EPS:
-1.78
ネットキャッシュフロー:
$-17.87M
1週間 パフォーマンス:
+0.13%
1か月 パフォーマンス:
-10.66%
6か月 パフォーマンス:
+15.36%
1年 パフォーマンス:
+8.74%
Lantern Pharma Inc Stock (LTRN) Company Profile
LTRN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
LTRN
Lantern Pharma Inc
|
3.98 | 43.74M | 0 | -19.25M | -17.87M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.39 | 107.73B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
654.48 | 62.04B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
475.91 | 62.73B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
836.39 | 51.09B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.29 | 34.67B | 398.11M | -1.03B | -868.57M | -5.7032 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-10-07 | 開始されました | H.C. Wainwright | Buy |
Lantern Pharma Inc (LTRN) 最新ニュース
Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers. - BioSpace
Lantern Pharma (NASDAQ: LTRN) Reports Complete Metabolic Response in Phase 1 LP-284 Trial at LL&M Congress - Digital Journal
Will Lantern Pharma Inc. stock recover after recent dropWeekly Risk Report & Growth-Oriented Investment Plans - newser.com
Using economic indicators to assess Lantern Pharma Inc. potentialIPO Watch & Target Return Focused Picks - newser.com
Lantern Pharma (LTRN) Reports Promising Phase 1 Trial Results for LP-284 - GuruFocus
Lantern Pharma presents LP-284 clinical data at 25th LL&M Congress - MarketScreener
Is Lantern Pharma Inc. stock attractive for income investorsInsider Selling & Weekly Return Optimization Plans - newser.com
What technical signals suggest for Lantern Pharma Inc. stockGDP Growth & Growth Focused Stock Pick Reports - Fundação Cultural do Pará
Is Lantern Pharma Inc. stock a buy before product launchesTrade Volume Summary & Advanced Technical Analysis Signals - newser.com
Lantern Pharma Inc. stock trendline breakdown2025 Technical Overview & Stepwise Trade Signal Implementation - newser.com
Will Lantern Pharma Inc. stock maintain dividend yieldQuarterly Trade Summary & Real-Time Sentiment Analysis - newser.com
Why Lantern Pharma Inc. stock is favored by pension fundsTrade Exit Summary & Low Risk Profit Maximizing Plans - newser.com
Lantern Pharma’s Promising Phase II Lung Cancer Study: Key Insights for Investors - TipRanks
Lantern Pharma’s LP-284 Study: A Potential Game-Changer in Cancer Treatment? - TipRanks
Lantern Pharma’s LP-184 Study: A Potential Game-Changer in Cancer Treatment - TipRanks
When is the best time to exit Lantern Pharma Inc.July 2025 Price Swings & Free Weekly Chart Analysis and Trade Guides - newser.com
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025 - BioSpace
How to interpret RSI for Lantern Pharma Inc. stock2025 Macro Impact & AI Forecasted Stock Moves - newser.com
Lantern Pharma Inc (LTRN) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):